Vertex Pharmaceuticals stock slips after Q3 revenue rises

Published on 11/03/2026 at 16:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharmaceuticals stock slips after third-quarter revenue rose 12 percent. Higher guidance and a November 30 FDA decision keep catalysts in view.

Quarterly growth and upcoming catalysts

Third-quarter revenue rose 12 percent year over year to USD 3.44 billion.
Vertex raised its 2026 revenue outlook to USD 13.15 billion to USD 13.25 billion.
The Crinetics acquisition expands the commercial portfolio, while a November 30 FDA decision could open a kidney franchise.

Vertex Pharma, US92532F1003, Illustration mit AI erstellt.

Vertex Pharmaceuticals reported third-quarter results on Monday, November 2, with revenue of USD 3.44 billion, up 12 percent from the year-earlier period. In its financial release, the company also raised its full-year revenue outlook.

Vertex Pharmaceuticals stock traded at 479.55 euros on Lang & Schwarz at 16:40 CET on Tuesday, November 3, 2026, 3.84 percent below the Xetra close of 498.70 euros on Monday, November 2. The quote was 5.20 percent below the 505.85 euros cited in the latest relevant report published earlier on Tuesday.

Investors can follow the real-time quote of Vertex Pharmaceuticals stock.

Growth broadens beyond cystic fibrosis

Cystic fibrosis remained the main revenue driver, with product revenue of USD 3.27 billion in the quarter. ALYFTREK revenue rose to USD 705.8 million from USD 247.0 million a year earlier, while CASGEVY generated USD 99.2 million and JOURNAVX USD 58.3 million.

The Crinetics Pharmaceuticals acquisition closed on September 1 and added PALSONIFY, which contributed USD 10.1 million in the quarter. Vertex said CASGEVY and JOURNAVX together should generate at least USD 500 million in 2026 revenue, while PALSONIFY is expected to contribute USD 40 million to USD 50 million.

Higher outlook comes with higher costs

Vertex raised 2026 revenue guidance from USD 13.1 billion to USD 13.2 billion to a range of USD 13.15 billion to USD 13.25 billion. The outlook includes a foreign-exchange benefit of approximately 150 basis points and reflects the addition of Crinetics.

Reported profitability was weaker because of acquisition-related expenses. GAAP net income fell to USD 653.6 million from USD 1.08 billion, while non-GAAP net income was USD 1.21 billion compared with USD 1.24 billion a year earlier. Vertex raised combined non-GAAP research and development, acquired in-process research and development, and selling, general and administrative expense guidance to approximately USD 6 billion.

FDA decision remains the next catalyst

The FDA is conducting a priority review of povetacicept for accelerated approval in immunoglobulin A nephropathy. Vertex said the PDUFA target action date is November 30, 2026. Approval would give the company a potential fifth commercial franchise in nephrology, adding a new growth avenue beyond cystic fibrosis and the recently expanded commercial portfolio.

The S&P 500 market environment provides the broader US equity backdrop.

More news and analyses on Vertex Pharmaceuticals stock.